Company Overview and News

0
Jaiprakash Associates Limited - News Clarification

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532532 JIPKY JPASSOCIAT

0
Jaiprakash Associates Limited - News Clarification

2018-06-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532532 JIPKY JPASSOCIAT

0
PM Modi to chair NITI Aayog meeting on Sunday

2018-06-15 freepressjournal.in
New Delhi: Prime Minister Narendra Modi will chair the fourth meeting of the Governing Council of NITI Aayog at Rashtrapati Bhawan on Sunday (June 17).
532532 JIPKY JPASSOCIAT

21
Jaiprakash Associates to submit plan to protect home buyers’ interest in Supreme Court

2018-06-15 freepressjournal.in
New Delhi: Crisis-hit Jaypee group flagship firm Jaiprakash Associates Ltd (JAL) will submit an appropriate proposal before the Supreme Court to protect the interest of its stuck home buyers.
UBNC 500116 AXB JIPKY IBN IDBI JPASSOCIAT 532525 532215 MAHABANK 532532 AXBKY 532179 SYNDIBANK AXBA ICICIBANK 533207 532276 JPINFRATEC CRPKY AXISBANK 532174 CORPBANK

0
Orient Cement cancels share purchase pact with Jaiprakash Associates

2018-05-31 thehindubusinessline
Jaiprakash Associates has informed the exchanges that it has received a letter from Orient Cement, terminating the share purchase agreement it had entered into on May 31, 2017, as the transaction did not take place within 12 months of the execution date. Jaiprakash Associates had entered into a share purchase agreement with Orient Cement for sale of equity shares constituting 74 per cent of the share capital of Bhilai Jaypee Cement (a joint venture with Steel Authority of India).
532532 ORIENTCEM JIPKY JPASSOCIAT 535754

0
Orient Cement shares jump nearly 7% on deal call-off

2018-05-31 moneycontrol
Shares of Orient Cement surged nearly 7 percent after the company announced the termination of the agreement to acquire two entities from Jaypee group firms. The stock surged 6.57 percent to end at Rs 129 on BSE. Intra-day, it jumped 15.24 percent to Rs 139.50.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

22
NCLAT admits Jaiprakash Associates’ plea over returning Jaypee Infratech’s 759 acres land

2018-05-31 livemint
New Delhi: The National Company Law Appellate Tribunal (NCLAT) on Thursday admitted an appeal by Jaiprakash Associates Ltd (JAL) challenging an order passed by National Company Law Tribunal’s (NCLT) Allahabad bench directing it to return 759 acres of land to its subsidiary Jaypee Infratech Ltd (JIL).
500116 AXB JIPKY IBN IDBI JPASSOCIAT 532215 532532 AXBKY AXBA ICICIBANK 533207 JPINFRATEC AXISBANK 532174 SBAZ

0
Orient Cement stock jumps 15% after deal to buy 2 units from Jaypee called off

2018-05-31 moneycontrol
Orient Cement share price rallied more than 15 percent intraday Thursday after the company called off a deal to acquire 2 units from Jaypee. Jaiprakash Associates lost 3 percent.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

0
Jaiprakash Associates Limited - Updates

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532532 JIPKY JPASSOCIAT

41
Market Live: Sensex up 150 pts, Midcap underperforms; Tech Mahindra, ONGC jump

2018-05-31 moneycontrol
Indian Oil Corporation, which has for decades been India's biggest company by turnover, last week posted a record net profit of Rs 21,346 crore in the fiscal year ended March 31, 2018 (FY 2017-18), up 12 per cent from Rs 19,106 crore in the last fiscal.
IOC 500325 JIPKY BHUSANSTL TCHQY 532755 532754 535754 UCLQY 500570 CLNDY 500055 RLNIY 500413 AXB EVSJF 532627 530965 ULTRACEMCO TECHM 500182 AXBA 500180 520051 TCS COALINDIA RELIANCE PUNJLLOYD GMQRY GMRINFRA 532538 TTNQY 533278 532215 THOMASCOOK 532540 AXISBANK RIGD HDFCBANK HEROMOTOCO TATAMOTORS ORIENTCEM ESI IBN UCLQF JPASSOCIAT 539207 AXBKY 532532 ICICIBANK 532693 HDB 532174 JAMNAAUTO JPPOWER HRTQY MANPASAND TTM

0
Orient Cement calls off deal to acquire 2 units from Jaypee

2018-05-31 moneycontrol
CK Birla Group firm Orient Cement has terminated the agreement to acquire two entities, Bhilai Jaypee Cement and Nigrie Cement Grinding Unit, from Jaypee group firms for a total consideration of Rs 1,946 crore.
532532 ORIENTCEM JIPKY 532627 JPPOWER JPASSOCIAT 535754

21
Jaypee Infra’s 700-acre land to remain with banks for now

2018-05-25 freepressjournal.in
New Delhi : The National Company Law Appellate Tribunal on Thursday admitted an appeal moved by ICICI Bank, Axis Bank and others challenging an order passed by the Allahabad bench of the National Company Law Tribunal directing Jaiprakash Associates to return over 700 acres of land to its subsidiary Jaypee Infratech.
500116 AXB JIPKY IBN IDBI JPASSOCIAT 532215 532532 AXBKY AXBA ICICIBANK 533207 JPINFRATEC AXISBANK 532174

43
Closing Bell: Sensex up over 300 pts, midcaps underperform; IT zooms, ONGC dips

2018-05-25 moneycontrol
Benchmark indices rose, driven by IT stocks, such as, Infosys and TCS on the back of a weak rupee. The IT index has gained 18 percent so far this year. The rupee has weakened by more than 7 percent so far this year, as surging crude oil prices weigh on India, the world’s third-largest importer, raising fears that soaring costs could drive up inflation and widen the trade deficit.
500325 JIPKY MS.PRE MS.PRF 531548 MS.PRG MS.PRA 534976 533207 AJANTPHARM BJJQY MS 500570 RLNIY AXB 524804 JETAIRWAYS 531335 AXBA BAJFINANCE MS.PRI FORTIS MS.PRK SOMANYCERA AUROPHARMA RELIANCE 532617 533155 BHRQY JUBLFOOD 532215 AXISBANK RIGD JBLWY BHARTIARTL 505324 TATAMOTORS MANUGRAPH 500034 IBN JPASSOCIAT 532843 AXBKY 532532 532454 VMART ICICIBANK 532331 JPINFRATEC 532174 ARBQY ZYDUSWELL TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...